- Home
- FINV vs IMCR Comparison
FINV vs IMCR Comparison
Compare FINV & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINV
- IMCR
- Stock Information
- Founded
- FINV 2007
- IMCR 2008
- Country
- FINV China
- IMCR United Kingdom
- Employees
- FINV N/A
- IMCR N/A
- Industry
- FINV Finance: Consumer Services
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FINV Finance
- IMCR Health Care
- Exchange
- FINV Nasdaq
- IMCR Nasdaq
- Market Cap
- FINV 1.9B
- IMCR 1.7B
- IPO Year
- FINV N/A
- IMCR 2021
- Fundamental
- Price
- FINV $7.09
- IMCR $34.26
- Analyst Decision
- FINV Strong Buy
- IMCR Buy
- Analyst Count
- FINV 2
- IMCR 9
- Target Price
- FINV $11.55
- IMCR $57.00
- AVG Volume (30 Days)
- FINV 1.3M
- IMCR 287.1K
- Earning Date
- FINV 11-17-2025
- IMCR 11-05-2025
- Dividend Yield
- FINV 4.03%
- IMCR N/A
- EPS Growth
- FINV 32.63
- IMCR N/A
- EPS
- FINV 1.49
- IMCR N/A
- Revenue
- FINV $1,927,901,951.00
- IMCR $356,145,000.00
- Revenue This Year
- FINV $11.56
- IMCR $29.71
- Revenue Next Year
- FINV $8.06
- IMCR $11.27
- P/E Ratio
- FINV $4.94
- IMCR N/A
- Revenue Growth
- FINV 7.84
- IMCR 26.78
- 52 Week Low
- FINV $5.72
- IMCR $23.15
- 52 Week High
- FINV $11.08
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- FINV 35.19
- IMCR 49.34
- Support Level
- FINV $7.09
- IMCR $33.92
- Resistance Level
- FINV $7.65
- IMCR $37.00
- Average True Range (ATR)
- FINV 0.25
- IMCR 1.45
- MACD
- FINV -0.00
- IMCR -0.06
- Stochastic Oscillator
- FINV 9.78
- IMCR 39.78
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.